Insulatard Innolet

Insulin Human, the active ingredient in Insulatard Innolet, is an intermediate‑acting insulin presented as a clear injectable solution for subcutaneous administration. It is used to lower elevated blood glucose levels in patients with type 1 and type 2 diabetes mellitus, providing basal insulin coverage.

GNH USA supplies Insulatard Innolet as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The product conforms to European Union regulatory requirements and is manufactured under GMP conditions to ensure consistent potency and safety.

Insulatard Innolet, an intermediate‑acting insulin, is used in the management of diabetes mellitus.

Type 1 diabetes mellitus: provides basal insulin to control fasting glucose levels. Type 2 diabetes mellitus: supplements endogenous insulin to improve overall glycaemic control. Gestational diabetes mellitus: offers basal insulin support to maintain target glucose levels during pregnancy.

Common Side Effects: - Hypoglycaemia: symptoms such as sweating, tremor, or confusion. - Injection‑site reactions: redness, swelling, or itching at the injection site. - Weight gain: modest increase in body weight over time. - Lipodystrophy: localized changes in fat tissue at injection sites. - Edema: mild fluid retention, especially in the lower extremities. - Headache: occasional mild headache.

Serious or Rare Side Effects: - Severe hypoglycaemia: loss of consciousness or seizures requiring immediate assistance. - Allergic reaction: rash, urticaria, or anaphylaxis. - Insulin antibodies: may affect insulin action or cause local inflammation. - Lipohypertrophy: significant accumulation of fatty tissue causing erratic insulin absorption. - Hypokalemia: low potassium levels, particularly with high insulin doses. - Acute pancreatitis: rare inflammation of the pancreas presenting with abdominal pain.

Precautions for Insulatard Innolet include careful monitoring and individualized dosing. - Dose adjustment: modify dose based on regular blood glucose monitoring and clinical response. - Hypoglycaemia risk: educate patients on recognizing and treating low blood sugar promptly. - Renal/hepatic impairment: consider dose reductions in patients with compromised organ function. - Pregnancy and lactation: use only if the potential benefit justifies the potential risk to the fetus or infant. - Concomitant medications: exercise caution when combined with sulfonylureas, beta‑blockers, or alcohol. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Insulatard Innolet may interact with several medications.

Major Interactions (Avoid): - Beta‑blockers: can mask hypoglycaemia symptoms, making detection difficult. - MAO inhibitors: may potentiate insulin's glucose‑lowering effect, increasing hypoglycaemia risk. - Alcohol: enhances insulin action and can precipitate severe hypoglycaemia.

Moderate Interactions (Monitor Closely): - Thiazide diuretics: may raise blood glucose, requiring possible insulin dose increase. - Corticosteroids: can increase glucose levels, necessitating careful monitoring. - Oral hypoglycaemic agents (e.g., sulfonylureas): additive glucose‑lowering effect, monitor for hypoglycaemia.